- Home
- / Oncolytics Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oncolytics Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.6
2024-10-29
Market Capitalization
$130.7 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating expense total | 17.2M | 19.7M | 25.0M | 25.8M | 26.5M | 33.4M | 25.5M | 28.7M |
| Depreciation and amortization | 95.0K | 486.0K | 446.0K | 452.0K | 392.0K | 403.0K | 87.0K | 70.0K |
| EBITDA | (17.2M) | (19.7M) | (25.0M) | (25.8M) | (26.5M) | (33.4M) | (25.5M) | (28.7M) |
| EBIT | (17.3M) | (20.1M) | (25.5M) | (26.2M) | (26.9M) | (33.8M) | (25.5M) | (29.1M) |
| Interest income | 174.0K | 179.0K | 121.0K | 99.0K | 528.0K | 1.3M | 975.0K | 386.0K |
| Pre tax profit | (16.5M) | (33.1M) | (22.5M) | (26.3M) | (24.8M) | (27.7M) | (22.7M) | (28.7M) |
| Income tax expense | 548.0K | 49.0K | 84.0K | 97.0K | 95.0K | 79.0K | ||
| Net Income | (17.0M) | (33.1M) | (22.5M) | (26.3M) | (24.8M) | (27.8M) | (22.8M) | (28.8M) |